Desvenlafaxine
Product Images NDC 35208-010

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 35208-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Intellipharmaceutics Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Devstructure (Devstructure)

Chemical structure of the active ingredient in Desvenlafaxine, showing the molecular arrangement of atoms including hydroxyl groups, a dimethylamino group, aromatic and cyclohexane rings, and associated carboxylic acid groups with water molecule.*

FDA Label Image

Fig4-study5relapsevs.randomization (Figure4)

A line graph comparing the estimated proportion of patients with relapse (%) over time to relapse in days from randomization. Two lines represent Desvenlafaxine Extended-Release Tablets 50 mg and placebo, showing relapse rates over approximately 180 days, with the placebo group having a higher proportion of relapse over time.*

FDA Label Image

Fig5-study6-relapsevs.randomization (Figure5)

A Kaplan-Meier curve chart showing the estimated proportion of patients with relapse over time in days from randomization. The chart compares desvenlafaxine extended-release tablets versus placebo, with the y-axis representing relapse proportion (%) and the x-axis representing time to relapse (days). The desvenlafaxine group is depicted with a blue line, and the placebo group with a red dashed line.*

FDA Label Image

Logo-intellipharmaceutics (Ipc Logo)

FDA Label Image

Dev-100mg-14c (Dev 100mg 14c)

Desvenlafaxine 100 mg extended-release tablets label showing dosage strength and form. The label lists desvenlafaxine succinate content, storage conditions, manufacturer IntelliPharmaCeutics Corp., and packaging size of 14 tablets. It includes pharmacist dispensing instructions and contact information with website, phone number, lot, and expiration placeholders.*

FDA Label Image

Dev-50mg-14c (Dev 50mg 14c)

Label for Desvenlafaxine extended-release tablets, 50 mg strength, manufactured by IntelliPharmaCeutics Corp. The label states each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. The package size is 14 tablets, Rx only, with storage instructions and contact information for questions or concerns. A barcode and NDC 35208-009-14 are also visible.*

FDA Label Image

Figure2 (Fig2final2)

A geometric mean ratio (90% CI) plot showing the pharmacokinetic changes in Desvenlafaxine when coadministered with the CYP3A4 inhibitor Ketoconazole. The chart presents the change relative to reference for Cmax and AUC values with corresponding confidence intervals.*

FDA Label Image

Figure1 (Figure1)

A forest plot illustrating the geometric mean ratio (90% confidence interval) of Cmax and AUC pharmacokinetic parameters for Desvenlafaxine in various population subgroups. These include categories of renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), gender (females), and age groups (65-75 years, >75 years). The x-axis shows change relative to reference with confidence intervals depicted for each subgroup.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart showing the geometric mean ratio (90% confidence interval) for pharmacokinetic parameters (Cmax and AUC) changes due to interactions with desvenlafaxine. The chart details data for substrates of CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 enzymes, including drugs like Desipramine, Midazolam, Tamoxifen, and Aripiprazole at various dosages. It illustrates changes relative to reference values, with points and confidence intervals plotted along a horizontal axis indicating change magnitude.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.